Onabotulinumtoxin Type A Improves Lower Urinary Tract Symptoms And Quality Of Life In Patients With Human T Cell Lymphotropic Virus Type 1 Associated Overactive Bladder.
Objetivo: Avaliar a eficácia da toxina botulínica no tratamento da bexiga hiperativa refratária a tratamento conservador em pacientes infectados pelo HTLV-1 .
Método: Série de casos de 10 pacientes submetidos a aplicação de 200Ui de onabotulinumtoxina tipo A e avaliados com OABSS e King's Health Questionnaire.
Resultados: a média da idade foi de 52+/- 14,5 anos, amostra predominantemente feminina, todos com hiperatividade detrusora documentada em estudo urodinâmico. A mediana (variação) do OABSS diminuiu de 13 (12-15) antes do tratamento para 1,0 (0-12) em 30 dias, para 03 (0-14) em 90 dias e 01 (1-15) em 180 dias (P<0,0001). Houve melhora de 8/9 domínios do King's Health Questionnaire.
Conclusão: A toxina onabotulínica intravesical reduziu o OABSS por um longo período e melhorou a qualidade de vida de pacientes infectados pelo HTLV-1 com bexiga hiperativa refratária.
Onabotulinumtoxin Type A Improves Lower Urinary Tract Symptoms And Quality Of Life In Patients With Human T Cell Lymphotropic Virus Type 1 Associated Overactive Bladder.
-
DOI: 10.22533/at.ed.5452108072
-
Palavras-chave: botox, onabotulinumtoxin A, overactive bladder, bexiga hiperativa, htlv, HTLV-1
-
Keywords: overactive bladder, onabotulinum toxin, HTLV-1
-
Abstract:
AIM: To evaluate the efficacy of the onabotulinum toxin type A in the treatment of HTLV-1 associated overactive bladder and its impact on QoL.
METHODS: Case series with 10 patients with overactive bladder refractory to conservative treatment with anticholinergic or physical therapy. They received 200Ui of onabotulinumtoxin type A intravesically and were evaluated by overactive bladder symptoms score (OABSS) and King´s Health Questionnaire.
RESULTS: The mean (SD) of the age was 52 + 14.5 years and 60% were female. All of them had confirmed detrusor overactivity on urodynamic study. Seven patients had HAM/TSP. The median and range of the OABSS was 13 (12-15) before therapy and decreased to 1.0 (0-12) on day 30 and to 03 (0-14) on day 90 (p<0.0001). There was a significant improvement in 8 of the 9 domains of the King´s Health Questionnaire after the intervention. Hematuria, urinary retention and urinary infection were the complications observed in 3 out of 10 patients. The mean time to request retreatment was 465 days.
CONCLUSION: Onabotulinum toxin type A intravesically reduced the OABSS with last long effect and improved the quality of life of HTLV-1 infected patients with severe overactive bladder.
-
Número de páginas: 15
- Rosana Andrade
- Cassios José Vítor de Oliveira
- Edgar Marcelino de Carvalho
- Jose Abraão Carneiro Neto
